You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR IDAMYCIN PFS

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for IDAMYCIN PFS

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002812 ↗	Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1996-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002812 ↗	Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia	Completed	Children's Oncology Group	Phase 3	1996-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002816 ↗	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1996-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002816 ↗	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	1996-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for IDAMYCIN PFS

Condition Name

Chart
Table

Condition Name for IDAMYCIN PFS
Intervention	Trials
Leukemia	14
Acute Myeloid Leukemia	8
Untreated Adult Acute Myeloid Leukemia	5
High Risk Myelodysplastic Syndrome	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for IDAMYCIN PFS
Intervention	Trials
Leukemia	30
Leukemia, Myeloid	22
Leukemia, Myeloid, Acute	21
Myelodysplastic Syndromes	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for IDAMYCIN PFS

Trials by Country

Map
Table

Trials by Country for IDAMYCIN PFS
Location	Trials
United States	178
Canada	15
Australia	7
China	3
Netherlands	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for IDAMYCIN PFS
Location	Trials
Texas	19
California	10
Missouri	7
North Carolina	6
New York	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for IDAMYCIN PFS

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for IDAMYCIN PFS
Clinical Trial Phase	Trials
Phase 3	3
Phase 2/Phase 3	1
Phase 2	15
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for IDAMYCIN PFS
Clinical Trial Phase	Trials
Completed	20
Recruiting	4
Withdrawn	3
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for IDAMYCIN PFS

Sponsor Name

Chart
Table

Sponsor Name for IDAMYCIN PFS
Sponsor	Trials
National Cancer Institute (NCI)	16
M.D. Anderson Cancer Center	14
Children's Oncology Group	4
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for IDAMYCIN PFS
Sponsor	Trials
Other	35
NIH	16
Industry	11
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.